NewAmsterdam Pharma reported a net loss of $241.6 million for the full year 2024, an increase from $176.9 million in 2023. The company's revenue increased to $45.6 million in 2024 from $14.1 million in 2023, primarily due to a clinical success milestone and development cost reimbursement. Cash and cash equivalents significantly increased to $771.7 million by year-end 2024, driven by successful financing rounds.
NewAmsterdam Pharma reported a full-year 2024 net loss of $241.6 million, compared to $176.9 million in 2023.
Full-year 2024 revenue increased to $45.6 million from $14.1 million in 2023, driven by a clinical success milestone and development cost reimbursement.
Cash and cash equivalents, along with marketable securities, totaled $834.2 million as of December 31, 2024, a substantial increase from $340.5 million in 2023.
The company completed enrollment for the PREVAIL Phase 3 CVOT trial in April 2024 and expects EMA submission in 2H25.
NewAmsterdam Pharma anticipates continued progress in clinical development and regulatory interactions, with an EMA submission expected in the second half of 2025. The company is also focusing on launch readiness for obicetrapib in the U.S. and Europe, if approved, supported by strong financial capital.
Analyze how earnings announcements historically affect stock price performance